JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Role of CD44 and CD24 Expression on 2-years Disease Free Survival in Patients with Advanced Epithelial Ovarian Carcinoma

  • 0Department of Obstetrics and Gynecology, Fatmawati Central General Hospital, Jakarta, Indonesia.
Asian Pacific Journal of Cancer Prevention : Apjcp +

|

February 28, 2024

|

February 28, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

High expression of CD44 and CD24 in ovarian cancer patients is linked to shorter disease-free survival. This suggests these markers may predict recurrence risk in advanced ovarian cancer.

Area Of Science

  • Oncology
  • Cancer Stem Cell Biology
  • Biomarker Research

Background

  • Ovarian cancer has a high mortality rate globally, with frequent recurrence despite optimal treatment.
  • Cancer stem cells expressing CD44 and CD24 are implicated in treatment resistance and disease recurrence.

Purpose Of The Study

  • To investigate the association between CD44 and CD24 expression levels and disease-free survival in advanced ovarian cancer patients.
  • To determine the prognostic value of CD44 and CD24 as potential biomarkers for ovarian cancer recurrence.

Main Methods

  • Retrospective cohort study of 48 advanced ovarian cancer patients treated between January 2019 and March 2023.
  • Immunohistochemical analysis of tumor tissues for CD44 and CD24 expression using the H-Score method.
  • Survival analysis, including ROC curve for cut-off determination and survival curves for disease-free survival assessment.

Main Results

  • High CD44 expression was observed in 47.9% of cases, associated with a median disease-free survival of 11 months (HR 5.05).
  • High CD24 expression was found in 50% of cases, linked to a median disease-free survival of 7 months (HR 7.73).
  • Combined high expression of CD44 and CD24 resulted in a median disease-free survival of 7 months.

Conclusions

  • Elevated expression of CD44 and CD24 significantly shortens disease-free survival in advanced ovarian cancer.
  • CD44 and CD24 represent potential prognostic biomarkers for predicting recurrence in ovarian cancer patients.

Keywords: